Financing is the fuel that drives growth in the biopharma sector, and participants at the BIO Asia-Taiwan Conference 2021 this week discussed different financing strategies for companies in the currently booming market.
Emerging companies continue to have a bigger role in pushing biotech innovation, and their presence is more important than ever, given the race for a COVID-19 solution. Those companies’ role in global R&D and new drug approvals was stressed by experts at the current BIO Asia-Taiwan conference.
With no new cases reported for more than 100 days, Taiwan appears to have successfully contained the spread of COVID-19 and has drawn attention to its medical achievements.
In the shadow of COVID-19, experts at the BIO Asia-Taiwan conference on Wednesday warned of present and future challenges for the biotech industry. Changes in manufacturing logistics and financial distress will continue to cause concern for the industry.
With no new cases reported for more than 100 days, Taiwan appears to have successfully contained the spread of COVID-19 and has drawn attention to its medical achievements. Experts said at BIO Asia-Taiwan conference this week that with continuous government and investor support, the East Asian nation could move further up to join other leading biotech players.
In the shadow of COVID-19, experts at the BIO Asia-Taiwan conference on Wednesday warned of present and future challenges for the biotech industry. Changes in manufacturing logistics and financial distress will continue to cause concern for the industry.
Emerging companies continue to have a bigger role in pushing biotech innovation, and their presence is more important than ever, given the race for a COVID-19 solution. Those companies’ role in global R&D and new drug approvals was stressed by experts at the current BIO Asia-Taiwan conference.
TAIPEI, Taiwan – Asian capital continues to play a key role in funding biotech development regionally and globally through private investments, M&A deals or IPOs. And 2018 was a particularly exciting one for cross-border investments and health care IPOs, said speakers at the BIO Asia conference. The total deal value of global biopharma IPOs and M&A deals hit a record $49 billion in 2018.
TAIPEI, Taiwan – Western pharma players might not be addressing diseases that are specific to or predominant in Asia, speakers said on the second day of the BIO Asia-Taiwan conference, making regional collaboration important for developing therapeutics targeting unmet needs at home.
TAIPEI, Taiwan – The three-day 2019 BIO Asia-Taiwan Conference and Exhibition opened on Wednesday to discuss how biotechnology could be the next growth engine for Asia. While figures are suggesting Asia is rising as a biotech powerhouse, the region needs to think beyond just capital, talent and patient pool, speakers said.
RSS
